ES2457398T3 - Variantes de eritropoyetina - Google Patents

Variantes de eritropoyetina Download PDF

Info

Publication number
ES2457398T3
ES2457398T3 ES06753630.0T ES06753630T ES2457398T3 ES 2457398 T3 ES2457398 T3 ES 2457398T3 ES 06753630 T ES06753630 T ES 06753630T ES 2457398 T3 ES2457398 T3 ES 2457398T3
Authority
ES
Spain
Prior art keywords
polynucleotide
epo
polypeptide
seq
helix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06753630.0T
Other languages
English (en)
Spanish (es)
Inventor
Andreas Meisel
Josef Prof. Dr. Priller
Christel Bonnas
Ulrich Dirnagl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charité – Universitätsmedizin Berlin
Original Assignee
Charité – Universitätsmedizin Berlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charité – Universitätsmedizin Berlin filed Critical Charité – Universitätsmedizin Berlin
Application granted granted Critical
Publication of ES2457398T3 publication Critical patent/ES2457398T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES06753630.0T 2005-05-13 2006-05-15 Variantes de eritropoyetina Expired - Lifetime ES2457398T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05010473A EP1736481A1 (en) 2005-05-13 2005-05-13 Erythropoietin variants
EP05010473 2005-05-13
PCT/EP2006/004564 WO2006120030A1 (en) 2005-05-13 2006-05-15 Erythropoietin variants

Publications (1)

Publication Number Publication Date
ES2457398T3 true ES2457398T3 (es) 2014-04-25

Family

ID=36753959

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06753630.0T Expired - Lifetime ES2457398T3 (es) 2005-05-13 2006-05-15 Variantes de eritropoyetina

Country Status (12)

Country Link
EP (2) EP1736481A1 (enExample)
JP (1) JP5231214B2 (enExample)
KR (1) KR101468737B1 (enExample)
CN (1) CN101175768B (enExample)
AU (1) AU2006245916B2 (enExample)
BR (1) BRPI0608769A2 (enExample)
CA (1) CA2608379C (enExample)
DK (1) DK1885747T3 (enExample)
ES (1) ES2457398T3 (enExample)
RU (1) RU2430162C2 (enExample)
WO (1) WO2006120030A1 (enExample)
ZA (1) ZA200709091B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020065576A1 (en) 2018-09-27 2020-04-02 Universidad Nacional Del Litoral Modified human erythropoietin

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1924276A4 (en) 2005-08-05 2009-07-22 Araim Pharmaceuticals Inc Antiperspirant peptides and their uses
US20100267576A1 (en) * 2007-05-02 2010-10-21 University Of Utah Research Foundation Compositions And Methods For Identifying And Treating Subjects At Risk Of Developing Type 2 Diabetes
DE102007031708A1 (de) 2007-07-06 2009-01-08 Dade Behring Marburg Gmbh Bestimmung der von Willebrand Faktor-Aktivität in Abwesenheit von Ristocetin
WO2009094172A2 (en) 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2011377617B2 (en) 2011-09-23 2018-03-08 Bluebird Bio, Inc. Improved gene therapy methods
KR101148191B1 (ko) * 2011-09-27 2012-05-23 김후정 에리스로포이에틴-유래 펩타이드 및 그 용도
DK2928921T3 (da) 2012-12-05 2021-04-19 Novartis Ag Sammensætninger og fremgangsmåder til antistoffer målrettet epo
CN105072914B (zh) 2013-02-06 2018-09-21 Nc医学研究公司 用于治疗神经变性的细胞疗法
ES2913530T3 (es) 2015-08-12 2022-06-02 Novartis Ag Métodos para tratar trastornos oftálmicos
HK1257024A1 (zh) 2015-08-31 2019-10-11 宾夕法尼亚大学 用於治疗伴侣动物的aav-epo
CN110475786A (zh) * 2017-02-27 2019-11-19 大邱庆北科学技术院 红细胞生成素衍生肽通过其对预防细胞损伤的作用的用途
CN107880109B (zh) * 2017-11-01 2019-08-30 复旦大学附属中山医院 一种促红细胞生成素来源肽及其制备方法和用途
US11566056B2 (en) 2020-05-26 2023-01-31 Sylus Co., Ltd Peptide and use thereof for treatment of disease of brain and nervous system
CN113376186B (zh) * 2021-05-12 2022-12-23 无锡科金生物科技有限公司 一种精准度高的智能红细胞叶酸检测仪及其检测方法
CA3222471A1 (en) * 2021-06-15 2022-12-22 Giovanni MARFIA Epo variants and modulators

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558006A (en) * 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
DE10043457A1 (de) 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
MXPA05000063A (es) * 2002-07-01 2005-04-08 Kenneth S Warren Inst Inc Citocinas recombinantes protectoras de tejido y acidos nucleicos que las codifican para la proteccion, restauracion y mejora de celulas, tejidos y organos respondedores.
WO2005025606A1 (en) 2003-09-09 2005-03-24 Warren Pharmaceuticals, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
US20040091961A1 (en) * 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
CA2563874A1 (en) * 2004-04-23 2005-11-03 Cambridge Antibody Technology Limited Erythropoietin protein variants

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020065576A1 (en) 2018-09-27 2020-04-02 Universidad Nacional Del Litoral Modified human erythropoietin

Also Published As

Publication number Publication date
CN101175768B (zh) 2013-09-11
WO2006120030A1 (en) 2006-11-16
KR20080021595A (ko) 2008-03-07
ZA200709091B (en) 2009-08-26
CN101175768A (zh) 2008-05-07
JP2008539745A (ja) 2008-11-20
EP1885747B1 (en) 2013-11-20
WO2006120030A8 (en) 2006-12-28
EP1736481A1 (en) 2006-12-27
CA2608379C (en) 2014-12-16
RU2430162C2 (ru) 2011-09-27
RU2007146455A (ru) 2009-06-20
CA2608379A1 (en) 2006-11-16
KR101468737B1 (ko) 2014-12-09
JP5231214B2 (ja) 2013-07-10
AU2006245916A1 (en) 2006-11-16
DK1885747T3 (en) 2014-02-24
BRPI0608769A2 (pt) 2010-01-26
AU2006245916B2 (en) 2012-03-15
EP1885747A1 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
US20190106470A1 (en) Erythropoietin variants
ES2327785T3 (es) Procedimientos y compuestos para inhibir el crecimiento de celulas neoplasticas.
RU2430162C2 (ru) Варианты эритропоэтина
AU2009276704A1 (en) Prominin-1 peptide fragments and uses thereof
JP6663428B2 (ja) Ｇｄｆ１５ポリペプチドを使用する、赤血球を増加させるための方法および組成物
KR20130122764A (ko) 항암 융합 단백질
AU2011210825A1 (en) Pro-angiogenic fragments of prominin-1 and uses thereof
KR20200090889A (ko) Cdkl5 발현 변이체 및 cdkl5 융합 단백질
HK1251001A1 (zh) Il-37变体
KR102348838B1 (ko) 트레일 트라이머와 암표적 펩타이드를 멀티디스플레이하는 페리틴 나노케이지 및 이의 항암제로서의 용도
WO2022099695A1 (en) Cd164 fusion and uses thereof
KR102221041B1 (ko) 신증후군 및 관련 병태의 치료 방법
ES2269506T3 (es) Terapia de regulacion genica que comprende ferritina.
US20220135640A1 (en) Cortistatin or an analogue thereof as a pharmaceutically active agent in latent form
JPWO2017069182A1 (ja) アミロイドβ及びタウに対するＤＮＡワクチン
CN113474013B (zh) 肌肉生长抑制素剪接变体衍生蛋白对肌肉生长抑制素信号的抑制及其利用
US7741464B2 (en) Compositions and methods of using CRMP-1 and its fragments for treating cancer
WO2017096431A1 (en) Proteinaceous molecules and methods of use
KR20150126234A (ko) Rage로부터 유래된 폴리펩티드 및 이를 유효성분으로 포함하는 뇌혈관질환의 예방 또는 치료용 약학적 조성물
WO2009116529A1 (ja) ポリペプチドおよび当該ポリペプチドを含む医薬組成物
ES2252032T3 (es) Modulacion de angiogenesis usando angiotensina-7 antiangiogenica y polinucleotidos codificantes para dicha sustancia para el tratamiento de tumores.